Results of the early disease activity control substudy (N=62): change from baseline to week 1
| Tocilizumab + DMARD (N=40) | Placebo + DMARD (N=22) | p Value | |
|---|---|---|---|
| DAS28 | |||
| n | 32 | 20 | 0.007 |
| Mean (SE) | −1.16 (0.22) | −0.27 (0.14) | |
| Patient's global assessment of pain (VAS 0–100 mm) | |||
| n | 35 | 20 | 0.01 |
| Mean (SE) | −12.2 (3.8) | 1.4 (4.6) | |
| Patient's global assessment of disease (VAS 0–100 mm) | |||
| n | 35 | 20 | 0.005 |
| Mean (SE) | −16.2 (4.1) | 0.8 (4.7) | |
| Physician's global assessment of disease (VAS 0–100 nm) | |||
| n | 36 | 20 | 0.0502 |
| Mean (SE) | −15.4 (3.0) | −5.6 (3.1) | |
| MDHAQ-PF | |||
| n | 36 | 20 | 0.829 |
| Mean (SE) | −0.5 (0.3) | −0.7 (0.3) | |
| TJC | |||
| n | 35 | 20 | 0.265 |
| Mean (SE) | −4.2 (1.9) | −7.2 (3.2) | |
| SJC | |||
| n | 35 | 20 | 0.683 |
| Mean (SE) | −3.0 (1.3) | −2.8 (2.7) | |
DAS28, disease activity score in 28 joints; DMARD, disease-modifying antirheumatic drug; MDHAQ-PF, multidimensional health assessment questionnaire for physical function; SE, standard error; SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale.